ETON

Eton Pharmaceuticals

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 1

Sell signal 2

consensus rating "Strong Buy"

EPS Below Expectations

Revenue Below Expectations

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About ETON

Eton Pharmaceuticals, Inc.

An innovative pharmaceutical company that having a product portfolio in Orphan Drugs, Hospital Products, and Royalty Products

Industry

Pharmaceutical

Established Date

04/27/2017

Listing Date

11/13/2018

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.etonpharma.com

Security Type

Common stock

Office address

21925 W. Field Parkway, Suite 235, Deer Park, IL 60010-7278

Business

Introduction

Eton Pharmaceuticals, Inc. was incorporated under the laws of the State of Delaware on April 27, 2017. The Company is an innovative pharmaceutical company focused on developing, acquiring and commercializing innovative products to meet the unmet needs of patients with rare diseases. The company currently has four commercial rare disease products, ALKINDI SPRINKLE for the treatment of adrenal insufficiency, glutamate for the treatment of hyperammonemia caused by deficiency of N-acetylglutamate synthase; betaine anhydrous for the treatment of homocysteinuria; nitticinone for the treatment of type 1 hereditary tyrosinemia, and three other product candidates are in late-stage development. The company is developing dehydrated alcohol injection, which has obtained orphan drug status for the treatment of methanol poisoning, ZENEO hydrocortisone auto-injector and ET-400 for the treatment of adrenal crisis.

Company Financials

EPS

ETON has released its 2024 Q4 earnings. EPS was reported at -0.02, versus the expected 0.00, missing expectations. The chart below visualizes how ETON has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ETON has released its 2024 Q4 earnings report, with revenue of 11.65M, reflecting a YoY change of 59.26%, and net profit of -598.00K, showing a YoY change of 73.49%. The Sankey diagram below clearly presents ETON’s revenue sources and cost distribution.